Skip to content
A Green Sign – Lifestyle
Author:
Biodexa Pharmaceuticals PLC
Biodexa provides R&D Update
November 9, 2026
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
October 15, 2026
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
September 23, 2026
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
September 15, 2026
Interim results for the six months ended June 30, 2026
September 14, 2026
Result of General Meeting
July 29, 2026
Result of Annual General Meeting
June 30, 2026
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
June 30, 2026
Postponement and Re-scheduling of Annual General Meeting
June 17, 2026
Biodexa issues letter to Shareholders
May 14, 2026